Budget Impact of Advanced Insulin Delivery Systems for the Management of Type 1 Diabetes
Authors' conclusion
This analysis highlights the health care budget that could be freed up through the use of AID systems, enabling decision-makers to improve glycemic control in people with T1D without increasing total expenditure.
Study context
- Population
- Hypothetical cohort of individuals with T1D in nine European countries; two populations by baseline HbA1c (≥8% and <8%)hypothetical cohort
- Participants
- 100 participants
- Exposure
- Automated insulin delivery (AID) systems vs MDI with isCGM
- Outcome
- Budgetary impact of improved glycemic control and reduced complication rates (health care costs of T1D complications)
- Follow-up
- 5-year time horizon
Methodological detailsmodelling study, 5-year time horizon, hypothetical cohort, nine European countries, treatment-neutral price
- Modelling study
- 5-year time horizon
- Hypothetical cohort
- Nine European countries
- Treatment-neutral price
Main finding
As reported in the abstract
5 years
- HbA1c ≥8%: overall complications reduction
- 61%
- HbA1c ≥8%: Diabetic ketoacidosis (DKA) reduction
- ∼70%
- HbA1c ≥8%: per-person 5-year cost savings across countries
- €1595 to €2810
- HbA1c <8%: complications excluding severe hypoglycemia events (SHEs) reduction
- 26%
- HbA1c <8%: DKA reduction
- ≈34%
- HbA1c <8%: per-person savings over 5 years
- €508 to €2819
Observational data: associations, not effects.
Original publication
Budget Impact of Advanced Insulin Delivery Systems for the Management of Type 1 Diabetes. Diabetes Technol Ther. Published 12 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →